Efficacy and Outcomes of Bempedoic Acid Versus Placebo in Patients with Hypercholesterolemia: an Updated Systematic Review and Meta-analysis of Randomized Controlled Trials

Overview

Journal Cardiovasc Endocrinol Metab

Specialty Cardiology & Vascular Diseases

Date 2024 Jun 24

PMID 38911912

Authors

Aman Goyal

Sangam Shah

Krishna Dahal

Mah I Kan Changez

Muhammad Daoud Tariq

Varisha Zuhair

Urooj Shamim

Haleema Qayyum Abbasi

Abhigan Babu Shrestha

Ranjit Sah

Amir Humza Sohail

Affiliations

Soon will be listed here.

Abstract

Introduction: Bempedoic acid (BA) has shown varied efficacy in managing hyperlipidemia. We conducted the most extensive up-to-date meta-analysis, the first to include recent studies by Nissen et al., which boast the largest sample size.

Methods: Literature search was done on Medline, EMBASE, and Cochrane Library. The primary endpoint was a change in low-density lipoprotein-cholesterol (LDL-C) levels, while secondary endpoints encompassed changes in lipid parameters, clinical endpoints, and safety endpoints. The least-square mean (LSM) percent change was utilized for lipid changes, with statistical significance set at < 0.05.

Results: This analysis included 12 randomized control trials with 22,249 participants. BA exhibited a substantial reduction in LDL-C levels [LSM % change, -24.34; 95% confidence interval (CI), -27.80 to -20.88; < 0.0001], total cholesterol levels (LSM % change, -16.62; 95% CI, -21.70 to -11.54; < 0.00001) and high-density lipoprotein-cholesterol (HDL-C) levels (LSM % change, -4.22; 95% CI, -5.51 to -2.92; < 0.00001) compared to the placebo.

Conclusions: BA significantly lowers LDL-C, total cholesterol, HDL-C, non-HDL-C, high sensitivity C reactive protein, and apolipoprotein levels.

References

Pang J, Chan D, Watts G . The Knowns and Unknowns of Contemporary Statin Therapy for Familial Hypercholesterolemia. Curr Atheroscler Rep. 2020; 22(11):64. PMC: 7459268. DOI: 10.1007/s11883-020-00884-2. View

Pinkosky S, Newton R, Day E, Ford R, Lhotak S, Austin R . Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. Nat Commun. 2016; 7:13457. PMC: 5133702. DOI: 10.1038/ncomms13457. View

Scirica B . Chronic angina: definition, prevalence, and implications for quality of life. Rev Cardiovasc Med. 2009; 10 Suppl 1:S3-10. DOI: 10.3909/ricm10S10002. View

Adnet F, Renault R, Jabre P, Kulstad E, Galinski M, Lapostolle F . Incidence of acute myocardial infarction resulting in sudden death outside the hospital. Emerg Med J. 2010; 28(10):884-6. DOI: 10.1136/emj.2010.095885. View

Ruscica M, Sirtori C, Carugo S, Banach M, Corsini A . Bempedoic Acid: for Whom and When. Curr Atheroscler Rep. 2022; 24(10):791-801. PMC: 9474414. DOI: 10.1007/s11883-022-01054-2. View

Ray K, Bays H, Catapano A, Lalwani N, Bloedon L, Sterling L . Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol. N Engl J Med. 2019; 380(11):1022-1032. DOI: 10.1056/NEJMoa1803917. View

Govindaraju A, Sabarathinam S . Bempedoic acid: A nonstatin drug for the management of hypercholesterolemia. Health Sci Rep. 2021; 4(4):e431. PMC: 8577242. DOI: 10.1002/hsr2.431. View

Kloner R, Chaitman B . Angina and Its Management. J Cardiovasc Pharmacol Ther. 2017; 22(3):199-209. DOI: 10.1177/1074248416679733. View

Ballantyne C, Banach M, Mancini G, Lepor N, Hanselman J, Zhao X . Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study. Atherosclerosis. 2018; 277:195-203. DOI: 10.1016/j.atherosclerosis.2018.06.002. View

10.

Xiao X, Luo Y, Peng D . Updated Understanding of the Crosstalk Between Glucose/Insulin and Cholesterol Metabolism. Front Cardiovasc Med. 2022; 9:879355. PMC: 9098828. DOI: 10.3389/fcvm.2022.879355. View

11.

Ballantyne C, Davidson M, MacDougall D, Bays H, DiCarlo L, Rosenberg N . Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled,.... J Am Coll Cardiol. 2013; 62(13):1154-62. DOI: 10.1016/j.jacc.2013.05.050. View

12.

Lalwani N, Hanselman J, MacDougall D, Sterling L, Cramer C . Complementary low-density lipoprotein-cholesterol lowering and pharmacokinetics of adding bempedoic acid (ETC-1002) to high-dose atorvastatin background therapy in hypercholesterolemic patients: A randomized placebo-controlled trial. J Clin Lipidol. 2019; 13(4):568-579. DOI: 10.1016/j.jacl.2019.05.003. View

13.

Rubino J, MacDougall D, Sterling L, Kelly S, McKenney J, Lalwani N . Lipid lowering with bempedoic acid added to a proprotein convertase subtilisin/kexin type 9 inhibitor therapy: A randomized, controlled trial. J Clin Lipidol. 2021; 15(4):593-601. DOI: 10.1016/j.jacl.2021.05.002. View

14.

Rossouw J . Lipid-lowering interventions in angiographic trials. Am J Cardiol. 1995; 76(9):86C-92C. DOI: 10.1016/s0002-9149(99)80476-7. View

15.

Grundy S, Stone N, Bailey A, Beam C, Birtcher K, Blumenthal R . 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2018; 139(25):e1082-e1143. PMC: 7403606. DOI: 10.1161/CIR.0000000000000625. View

16.

Nissen S, Lincoff A, Brennan D, Ray K, Mason D, Kastelein J . Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. N Engl J Med. 2023; 388(15):1353-1364. DOI: 10.1056/NEJMoa2215024. View

17.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009; 151(4):264-9, W64. DOI: 10.7326/0003-4819-151-4-200908180-00135. View

18.

Cicero A, Fogacci F, Hernandez A, Banach M . Efficacy and safety of bempedoic acid for the treatment of hypercholesterolemia: A systematic review and meta-analysis. PLoS Med. 2020; 17(7):e1003121. PMC: 7365413. DOI: 10.1371/journal.pmed.1003121. View

19.

Bardolia C, Amin N, Turgeon J . Emerging Non-statin Treatment Options for Lowering Low-Density Lipoprotein Cholesterol. Front Cardiovasc Med. 2021; 8:789931. PMC: 8635697. DOI: 10.3389/fcvm.2021.789931. View

20.

Guijarro C, Cosin-Sales J . LDL cholesterol and atherosclerosis: The evidence. Clin Investig Arterioscler. 2021; 33 Suppl 1:25-32. DOI: 10.1016/j.arteri.2020.12.004. View